Pharmacy and Therapeutics - January 2008 - (Page 34) Aripiprazole and Tardive Dyskinesia REFERENCES 1. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington DC: American Psychiatric Publishing; 1992. 2. Young AH. Treatment of bipolar disorder with antipsychotic medication: Issues shared with schizophrenia. J Clin Psychiatry 2007;68(Suppl 6):24–25. 3. Stachnik JM, Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder. Ann Pharmacother 2007; 41(4):626–634. 4. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):843–853. 5. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis. J Clin Psychiatry 2007;68(6):826–831. 6. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very-high-risk patients. Biol Psychiatry 2003;53(12):1142–1145. 7. Seeman P. An update of fast-off dopamine D 2 atypical antipsychotics. Am J Psychiatry 2005;162:1984–1985. 8. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptor, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123–134. 9. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: A review of the new generation antipsychotics. Int Clin Psychopharmacol 2005;20:183–198. 10. Grunder G, Carisson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974–977. 11. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord 2006; 21:589–598. 12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 2001;30(2):239–245. 13. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectrums 2006;11(6):435–439. 14. Zacher JL, Hatchett AD. Aripiprazole-induced movement disorder. Am J Psychiatry 2006;163(1):160–161. 15. Brahm NC, McElwain DL, Brown RC. Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disability. Am J Health Syst Pharm 2007;4:827–829. 16. Sajbel TA, Cheney EM, DeQuardo JR. Aripiprazole-associated dyskinesia. Ann Pharmacother 2005;39(1):200–201. 17. Evcimen YA, Evcimen H, Holland J. Aripiprazole-induced tardive dyskinesia: The role of tamoxifen. Am J Psychiatry 2007;164(9): 1436–1437. 18. Grant MJ. Baldessarini RJ. Possible improvement of neurolepticassociated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005;39(11):1953. 19. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 2005;50(3):188. 20. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48(11):771–772. 21. Rizos E, Douzenis A, Gournellis R. Tardive dyskinesia in a patient treated with quetiapine. World J Biol Psychiatry 2007;1–4 (electronic version). Available at: www.informaworld.com/smpp/ title~content=t713721967~db=all. Accessed December 3, 2007. 22. Llorca P-M, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 2002;17;129–138. I Impact of Bipolar Disorder on the Family continued from page 28 26. Hill MK, Sahhar M. Genetic counseling for psychiatric disorders. Med J Austral 2006;185:507–510. 27. Rajagopalan K, Kleinman NL, Brook RA, et al. Costs of physical and mental comorbidities among employees: A comparison of those with and without bipolar disorder. Curr Med Res Opin 2006; 22(3):443–452. 28. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181–188. 29. Valtonen H, Souminen K, Mantere O, et al. Suicidal ideation and attempts in bipolar I and II disorders. J Clin Psychiatry 2005;66: 1456–1462. 30. Simon GE, Ludman EJ, Bauer MS, et al. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry 2006;63:500–508. 31. Hirschfeld RMA, Vornik LA. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry 2004;65(Suppl 15):5–9. 32. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999;50:1303–1308. I COMING SOON TO P&T EDITORIAL: Changing Diabetes Care: An Opportunity for the Feds David B. Nash, MD, MBA DRUG FORECAST: Aliskiren (Tekturna): A Novel Approach to Inhibition of the Renin–Angiotensin–Aldosterone System Julie Cromer, PharmD, and Simona Peker, PharmD FEATURE ARTICLES: Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes Cristin Williams, PharmD, Ji Koo, PharmD, and Jonathan Hass, PharmD A Pilot Review: Assessing the Impact of Computer Software Modification on Compliance with Recommendations for Self-Monitoring Of Blood Glucose Anita D. Patel, BA, PharmD; Viktoria Kharlamb, PharmD; Arthur P. Reiter, BS, MS; and Ron Lovly, MS, RPh 34 P&T® • January 2008 • Vol. 33 No. 1 http://www.informaworld.com/smpp/title~content=t713721967~db=all http://www.informaworld.com/smpp/title~content=t713721967~db=all
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.